Day Three – Research and Development

For day three of the ADA Scientific Sessions 2015 we focused on wholesale nfl jerseys the education and the research on show in the exhibition hall. As you can see form the photo below, there are several thousand poster on display, each one is an abstract of some new research being done into Diabetes!

It has been noted on social media in the past about research into Diabetes type-1 and type-2 being focused on the same topics over and over again, so we took the day as an opportunity to find out just how much is really going on.

 Poster hall

With tailored care programs a major focus of attention amongst several academics, as discussed by Linda Delahanty on the first day in her talk on this specific subject, we set about exploring the exhibition hall, speaking to researchers, academics, and viewing posters in the poster hall to find out what others in the field have discovered and/or are trying to find.

Without delving into the more serious scientific work on display, we found that many posters in the ‘exercise’ section focused on recognising the needs of patients, that Research no matter how little, activity is key to managing Type 2 Diabetes, and that while there is no immediate effect, increased activity over a period of 3 months can hugely affect insulin resistance in people with Type-1 Diabetes, increasing sensitivity in muscle tissue (Lisa Guth, University of Michigan).

First of all a presentation Hangover from Dr Pratik Choudhary on the merits of the Medtronic 640g and it’s Safeguard technology provided an insight into how the latest advancement in pump technology works from a scientific perspective; graphs showing some staggering figures for including some 3000+ triggers of the safeguard function (where the pump stops insulin delivery if it notices a новогодних falling pattern in blood glucose readings) over the course of 30 days from it’s participants.

Of course the system only works properly if you combine it with the Medtronic Enlite sensor, however these are harder to cheap jerseys find in the UK than their Dexcom counterparts, and this is something we are working on improving as a result of the show.

A more in-depth chat with Dr Pratik Choudhary yielded further discussion on closed-loop systems (once again the Medtronic 640g and Safeguard), and how they can benefit people who do not feel in control of their Diabetes as much as others, by teaching them how to control hypos and recognising when they are heading into and out of them.

An especially fascinating research stand was that of Januvia, a Type-2 treatment drug. The stand consisted of four Occulus Rift headsets and computers, where visitors could sit down and experience a opens 1st person tour inside an animated pancreas and see how strong and actually quite vicious the medication on display was. Not only was this stand intriguing for its presentation, for the simple evidence that interactive technology is becoming more prevalent in the medical and pharmaceutical world, not just in the gaming industry.

Jenuvia 

As well as learning about existing research projects, we also set about exploring the ‘industry’ side of social media, and how companies are embracing it for product development – after all we are the ones who are supposed to benefit wholesale jerseys from their research.

South Korean manufacturers Dana made it clear that they do not engage patients or their customers in any way, which we found pretty shocking; after all how are they supposed to know if their products are beneficial or not?

Pharmaceutical giants Sanofi however have taken a very different approach, speaking with us directly about why social media and the patient voice is vital in the modern day and for developing future technology. We will have a video interview for you soon with their social media team.  AstraZeneca admitted that their patient engagement is cheap nba jerseys in need of improvement, however they have said that they are working on new ideas, while Medtronic’s engagement is clear, especially with their use of Twitter.

As far as research and exploration of Diabetes and it’s future goes, the ADA Scientific Sessions provided a major insight into what is going on around the world. We have found that many organisations, albeit at different rates and through different methods, are recognising that personalised plans are far more successful than ‘one size fits all’ methodologies, that while the technology we have Day now is very good, their still needs to be a lot of work to provide a ‘solution’ in the management of T1 and T2 Diabetes.